Seltorexant for Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing seltorexant, a new medication, to help people with depression and sleep problems who haven't improved enough with their current antidepressants. Seltorexant works by blocking a brain receptor to help improve sleep and mood.
Will I have to stop taking my current medications?
The trial does not specify that you need to stop taking your current medications. In fact, it requires participants to continue taking a stable dose of their current SSRI or SNRI antidepressant.
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Adults with major depressive disorder and insomnia who haven't improved enough on SSRIs or SNRIs can join. They must have a BMI of 18-40, stable health, no severe mental disorders like bipolar or psychosis, no serious sleep disorders other than insomnia, and not be at high risk for suicide.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Treatment
Participants receive either seltorexant or placebo as adjunctive therapy to antidepressants
Open-label Treatment
Eligible participants receive seltorexant daily to assess long-term safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Seltorexant
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University